Back to results
US 2022/0090008 A1Published application
Colony forming medium and use thereof
AssigneeCynata Therapeutics Limited
InventorsIGOR SLUKVIN, GENE UENISHI, DEREK HEI, DIANA DRIER
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCynata Therapeutics Limited
InventorsIGOR SLUKVIN, GENE UENISHI, DEREK HEI, DIANA DRIER
Estimating the term…
The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.
A mesenchymal stem cell (MSC) expressing miR-145-5p, miR-181b-5p and miR-214-3p, but not miR-127-3p or miR-299-5p.
A mesenchymal colony forming medium (M-CFM), comprising about 1 mM LiCl and about 5 ng/mL to about 100 ng/mL FGF2, but excluding PDGF.
A composition comprising LiCl and FGF2, but excluding PDGF, that, when admixed with a liquid comprising water, produces an M-CFM comprising about 1 mM LiCl and about 5 ng/mL to about 100 ng/mL FGF2.
Dependencies are inferred from the claim text.